|
|
|
Insider
Information: |
Higgins John L |
Relationship: |
Director |
City: |
Palo Alto |
State: |
CA |
|
|
Insider
Summary: |
|
|
|
Companies Owned : |
3 |
|
Direct
Shares |
2,806,928 |
|
Indirect Shares
|
0 |
|
|
Direct
Value |
$49,664,092 |
|
|
Indirect Value
|
$0 |
|
|
Total
Shares |
2,806,928 |
|
|
Total
Value |
$49,664,092 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
Total
Filings :
|
0
|
11
|
Stock
price went up :
|
0
|
5
|
Stock
price went down : |
0
|
6
|
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
Percentage
Gain/Loss : |
0.0%
|
-38.4%
|
|
|
|
|
|
|
Holdings
:
Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold |
|
Ligand Pharmaceuticals Inc |
LGND |
Director |
2022-12-28 |
417,695 |
2007-02-01 |
0 |
Premium* |
|
Techne Corp |
TECH |
Director |
2024-05-14 |
36,608 |
2013-10-31 |
0 |
Premium* |
|
OmniAb, Inc |
OABI |
Director |
2024-01-30 |
2,352,625 |
2022-11-01 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
Records found :
165 |
Free Registration Required For Full Results. Limit: 25
|
|
Download |
Page 4 of 7
|
Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
LGND |
Ligand Pharmaceuticals In... |
Chief Executive Officer |
|
2019-03-13 |
4 |
B |
$114.29 |
$285,725 |
D/D |
2,500 |
141,399 |
2.81 |
- |
|
LGND |
Ligand Pharmaceuticals In... |
Chief Executive Officer |
|
2019-05-14 |
4 |
B |
$113.50 |
$283,750 |
D/D |
2,500 |
143,899 |
2.81 |
- |
|
LGND |
Ligand Pharmaceuticals In... |
Chief Executive Officer |
|
2019-05-31 |
4 |
B |
$108.20 |
$108,202 |
D/D |
1,000 |
144,899 |
2.81 |
- |
|
LGND |
Ligand Pharmaceuticals In... |
Chief Executive Officer |
|
2019-07-31 |
4 |
B |
$95.45 |
$176,583 |
D/D |
1,850 |
146,749 |
2.81 |
- |
|
LGND |
Ligand Pharmaceuticals In... |
Chief Executive Officer |
|
2016-02-15 |
4 |
D |
$85.97 |
$214,237 |
D/D |
(2,492) |
130,497 |
0 |
- |
|
LGND |
Ligand Pharmaceuticals In... |
Chief Executive Officer |
|
2017-02-15 |
4 |
D |
$104.28 |
$448,821 |
D/D |
(4,304) |
118,360 |
0 |
- |
|
LGND |
Ligand Pharmaceuticals In... |
Chief Executive Officer |
|
2017-02-24 |
4 |
D |
$100.38 |
$480,118 |
D/D |
(4,783) |
122,745 |
0 |
- |
|
LGND |
Ligand Pharmaceuticals In... |
Chief Executive Officer |
|
2017-03-08 |
4 |
D |
$106.92 |
$157,493 |
D/D |
(1,473) |
143,171 |
0 |
- |
|
LGND |
Ligand Pharmaceuticals In... |
Chief Executive Officer |
|
2017-10-13 |
4 |
D |
$143.04 |
$249,462 |
D/D |
(1,744) |
148,811 |
0 |
- |
|
LGND |
Ligand Pharmaceuticals In... |
Chief Executive Officer |
|
2017-12-28 |
4 |
D |
$138.66 |
$720,893 |
D/D |
(5,199) |
146,050 |
0 |
- |
|
LGND |
Ligand Pharmaceuticals In... |
Chief Executive Officer |
|
2018-02-15 |
4 |
D |
$157.18 |
$981,118 |
D/D |
(6,242) |
96,458 |
0 |
- |
|
LGND |
Ligand Pharmaceuticals In... |
Chief Executive Officer |
|
2018-03-06 |
4 |
D |
$165.87 |
$494,624 |
D/D |
(2,982) |
107,419 |
0 |
- |
|
LGND |
Ligand Pharmaceuticals In... |
Chief Executive Officer |
|
2019-01-23 |
4 |
D |
$111.78 |
$756,192 |
D/D |
(6,765) |
126,090 |
0 |
- |
|
LGND |
Ligand Pharmaceuticals In... |
Chief Executive Officer |
|
2019-02-15 |
4 |
D |
$120.86 |
$594,269 |
D/D |
(4,917) |
133,982 |
0 |
- |
|
LGND |
Ligand Pharmaceuticals In... |
Chief Executive Officer |
|
2019-12-20 |
4 |
D |
$105.87 |
$714,517 |
D/D |
(6,749) |
153,614 |
0 |
- |
|
LGND |
Ligand Pharmaceuticals In... |
Chief Executive Officer |
|
2020-02-13 |
4 |
D |
$95.68 |
$479,261 |
D/D |
(5,009) |
196,730 |
0 |
- |
|
LGND |
Ligand Pharmaceuticals In... |
Chief Executive Officer |
|
2020-02-15 |
4 |
D |
$97.23 |
$497,429 |
D/D |
(5,116) |
205,173 |
0 |
- |
|
LGND |
Ligand Pharmaceuticals In... |
Chief Executive Officer |
|
2020-11-09 |
4 |
D |
$81.77 |
$200,991 |
D/D |
(2,458) |
222,113 |
0 |
- |
|
LGND |
Ligand Pharmaceuticals In... |
Chief Executive Officer |
|
2020-12-08 |
4 |
D |
$87.52 |
$147,296 |
D/D |
(1,683) |
235,087 |
0 |
- |
|
LGND |
Ligand Pharmaceuticals In... |
Chief Executive Officer |
|
2021-01-25 |
4 |
D |
$156.01 |
$1,160,870 |
D/D |
(7,441) |
243,422 |
0 |
- |
|
LGND |
Ligand Pharmaceuticals In... |
Chief Executive Officer |
|
2021-02-05 |
4 |
D |
$203.03 |
$602,999 |
D/D |
(2,970) |
343,060 |
0 |
- |
|
LGND |
Ligand Pharmaceuticals In... |
Chief Executive Officer |
|
2021-02-15 |
4 |
D |
$172.46 |
$898,862 |
D/D |
(5,212) |
337,848 |
0 |
- |
|
LGND |
Ligand Pharmaceuticals In... |
Chief Executive Officer |
|
2022-01-26 |
4 |
D |
$113.68 |
$1,050,744 |
D/D |
(9,243) |
349,018 |
0 |
- |
|
LGND |
Ligand Pharmaceuticals In... |
Chief Executive Officer |
|
2022-02-15 |
4 |
D |
$123.68 |
$732,557 |
D/D |
(5,923) |
340,593 |
0 |
- |
|
LGND |
Ligand Pharmaceuticals In... |
Chief Executive Officer |
|
2022-11-30 |
4 |
D |
$72.90 |
$714,639 |
D/D |
(9,803) |
416,928 |
0 |
- |
|
165 Records found
|
|
Page 4 of 7 |
|
Free Registration Required For Full Results. Limit: 25
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|